Biotechnology

Salarius Pharmaceuticals

Salarius Pharmaceuticals released FY2025 9 Months Earnings on November 14, 2025 (EST) with actual revenue of USD 0 and EPS of USD -1.8137

Salarius Pharmaceuticals released FY2025 Q3 earnings on November 14 (EST), actual revenue USD 0 (forecast USD 0), actual EPS USD -1.8137 (forecast USD -706.7996)

Salarius Pharmaceuticals released FY2025 Semi-Annual earnings on August 12 (EST) with actual revenue of USD 0 and EPS of USD 0

Salarius Pharmaceuticals released FY2025 Q2 earnings on August 12 (EST), actual revenue USD 0 (forecast USD 0), actual EPS USD -0.4511 (forecast USD -46.8)

Salarius Pharmaceuticals Conducting Seclidemstat Clinical Trial for MDS and CMML Patients

Salarius Updates Merger Agreement with Decoy

Salarius Pharmaceuticals released FY2025 Q1 earnings on May 14 (EST), actual revenue USD 0 (forecast USD 0), actual EPS USD 0 (forecast USD -701.9996)

Salarius Pharma Reports $5.6 Million Net Loss in 2024, Considering Merger with Decoy Therapeutics

Salarius Pharmaceuticals released FY2024 Q4 earnings on March 21 (EST), actual revenue USD 0 (forecast USD 0), actual EPS USD 0 (forecast USD -805.20)

Salarius Pharmaceuticals released FY2024 annual earnings on March 21 (EST), actual revenue 0 USD (forecast 0 USD), actual EPS -5.7947 USD (forecast -214.48 USD)

Salarius Pharmaceuticals released FY2024 Q3 earnings on November 14 (EST), actual revenue USD 0 (forecast USD 0), actual EPS USD -11.3754 (forecast USD -803.9996)

Salarius Pharmaceuticals released FY2024 Cumulative 3Q Earnings on November 14 (EST), Revenue: 0, EPS: -6.4021

Salarius Pharmaceuticals released FY2024 Semi-Annual earnings on August 9 (EST) with actual revenue of USD 0 and EPS of USD 0

Salarius Pharmaceuticals released FY2024 Q2 earnings on August 9 (EST), actual revenue USD 0 (forecast USD 0), actual EPS USD 0 (forecast USD -803.9996)

Salarius Pharmaceuticals Decides to Close Seclidemstat Clinical Trial for Ewing Sarcoma

Salarius Pharmaceuticals: FDA to partially pause clinical trial evaluating the combination of Seclidemstat (SP-2577) and Azacitidine

Salarius Pharmaceuticals released FY2024 Q1 earnings on May 13 (EST), actual revenue USD 0 (forecast USD 0), actual EPS USD 0 (forecast USD -803.9996)

Salarius Pharmaceuticals released FY2023 earnings on March 22 (EST), actual revenue USD 0 (forecast USD 0), actual EPS USD 0 (forecast USD -791.9996)

Salarius Pharmaceuticals released FY2023 Q4 earnings on March 22 (EST), actual revenue USD 0 (forecast USD 0), actual EPS USD 0 (forecast USD -178.80)

Salarius Pharmaceuticals released FY2023 9 Months Earnings on November 9, 2023 (EST) with actual revenue of USD 0 and EPS of USD 0

Agape ATP

Co-Diagnostics

PicoCELA

Liminatus Pharma

Akanda

Defiance Daily Target 2X Long RGTI ETF

Tradr 2X Long RGTI Daily ETF

Tradr 2X Long QBTS Daily ETF

Netcapital

NewGenIvf

SLRX

SBIO

VRTX

ARMP

Arna Pharma Inc. and Slate Run Pharmaceuticals have signed a Memorandum of Understanding (MOU) to establish a joint venture aimed at creating a scaled-up U.S. specialty pharmaceutical platform. This collaboration will leverage Arna's development capabilities and Slate Run's commercial and regulatory infrastructure to focus on branded products, 505(b)(2) medicines, and specialized generics. The joint venture is expected to enhance market access and accelerate the introduction of specialized generics in high-value therapeutic segments. Leadership from both companies will ensure seamless integration and uphold regulatory compliance and product quality standards.

prnewswire

Proshares Ultra Nasdaq Biotech

ALPS Medical Breakthrough

iShares Global Healthcare

Verona Pharma

iShares Biotechnology ETF

Invesco Biotechnology & Genome ETF

Health Care Select Sector SPDR

iShares US Pharma

SPDR S&P Biotech

Sarepta Therap

Vertex Pharma

VG Health

Armata Pharmaceuticals

Invesco Nasdaq Biotechnology ETF

13:00 ETArna Pharma Inc. and Slate Run Pharmaceuticals to form a Joint Venture to Create Scaled-Up U.S. Specialty Pharmaceutical Platform

BPMC

Slate Medicines has raised $130 million in a Series A financing round to advance its anti-PACAP migraine therapies, specifically the monoclonal antibody SLTE-1009. This funding follows the in-licensing of SLTE-1009 from DartsBio Pharmaceuticals. The company aims to provide a novel mechanism for migraine prevention, targeting patients who do not respond well to existing treatments. CEO Gregory Oakes emphasized the potential of SLTE-1009 for improved patient access through convenient subcutaneous dosing. The financing round also brings new members to the Board of Directors from RA Capital, Forbion, and Foresite Capital.

Pharmaceutical Technology

Blueprint Med

VanEck Biotech ETF

First Trust NYSE Arca Biotech Index Fd

Ark Genomic Revolution ETF

Slate Medicines raises $130m in funds to progress anti-PACAP treatments

SMLR

In Charlestown, South Carolina on February 24, 2026, Salus Scientific, known as the Occupational Wellness Company, responded to the industry-wide garment recalls by reassuring its dedication to offering top-tier radiation protection core material globally. They emphasized their commitment to quality and safety in the face of recent challenges.

Unusual Whales

Semler Scientific

Brain Scientific Inc.

iShares US Medical Devices

SPDR S&P Health Equip

Salus Scientific vows to maintain quality and safety standards despite industry recalls. - Company: Salus Scientific- Location: Charleston, S.C- Date: Feb. 24, 2026- Focus: Superior quality and safety- Key Message: Reaffirming commitment to top-tier radiation protection materials.

DCOY

Salarius Pharmaceuticals has rebranded as Decoy Therapeutics, now trading under the Nasdaq ticker DCOY. The company is focusing on peptide conjugate therapeutics. Meanwhile, the global COVID-19 situation remains critical, with over 10 million confirmed cases and a death toll exceeding 500,000. Despite lockdowns, some regions face a resurgence in cases, prompting health officials to stress the importance of safety guidelines. Researchers are actively working on vaccine development, with several candidates in clinical trials as governments adapt their strategies to combat the pandemic.

Decoy Therapeutics

Salarius Pharmaceuticals becomes Decoy Therapeutics with Nasdaq ticker DCOY, emphasizing peptide conjugate therapeutics.

Salarius Pharmaceuticals has rebranded as Decoy Therapeutics, adopting the Nasdaq ticker symbol DCOY, to emphasize its focus on peptide conjugates. In a separate report, a recent natural disaster has impacted 8.7 million people, damaging over 12,000 homes and displacing 35,000 individuals. More than 2,500 emergency shelters have been established, with ongoing rescue efforts involving over 1,000 trained personnel. The government has allocated $50 million for recovery, alongside donations from various organizations to support affected communities.

"Salarius Pharmaceuticals rebrands as Decoy Therapeutics, with Nasdaq ticker symbol DCOY, highlighting peptide conjugate focus."

CELG.RT

MNTS

Overview of the US Stock Market Recently, the US stock market has shown strong sector rotation, with the technology and pharmaceutical sectors performing particularly well. There seems to be a strong interest in small-cap stocks and thematic stocks, driving significant increases in several stocks. The market pace is fast, volatility has increased, short-term enthusiasm has clearly risen, and investor sentiment is positive. The stock with the largest movement, SMX Security Matters, saw its price soar by 85.74%, with significantly increased trading volume, indicating strong market attention. There is a noticeable influx of funds, driving rapid price increases and heightened short-term sentiment. Strong stocks: 1. Bristol-Myers Squibb Company: up 63.09%, with a five-day increase of 76.00%, the leader in the pharmaceutical sector. 2. Momentus: up 58.14%, with a ten-day increase of 57.15%, a star stock in the technology sector. 3. Monte Rosa Therapeutics: up 49.59%, with a six-month increase of 362.58%, a dark horse in the pharmaceutical field. 4. Regencell Bioscience: up 48.74%, with increased trading volume and heightened market attention. 5. NovaBay Pharmac: up 44.93%, reaching a new 60-day high, showing strong performance in the pharmaceutical sector. 6. Treasure Gbl: up 44.39%, with increased trading volume and noticeable fund inflow

Price Alert

SMX Security Matters

Bristol-Myers Squibb Company

Momentus

Monte Rosa Therapeutics

Regencell Bioscience

Novabay Pharmac

Treasure Gbl

Sky Quarry

Ventyx Biosciences

Neumora Therapeutics

Cohen

Opendoor Tech Series A - CW26

Ascent Solar Tech

Opendoor Tech Series Z - CW26

374Water

Next Tech

Sable Offshore

Datavault AI

Trident Digital Tech

Opendoor Tech Series K - CW26

Stablecoin Development

U.S. stock market movement update: SMX surged 85%, Bristol-Myers rose 63%, Cohen fell 30%, and short-term capital in the market is active

Salarius Pharmaceuticals, Inc. will change its name to Decoy Therapeutics Inc. and its Nasdaq ticker symbol to DCOY, effective January 8, 2026. This rebranding reflects the company's focus on developing next-generation peptide-conjugate therapeutics. The company aims to advance its lead antiviral program and expand its pipeline while leveraging AI for candidate selection. Decoy Therapeutics is positioned to pursue strategic collaborations and non-dilutive funding, with a focus on addressing respiratory viruses and GI cancers. The changes do not affect the number of shares or company operations.

StockTitan

Salarius Pharmaceuticals Changes Corporate Name to Decoy Therapeutics and Nasdaq Ticker Symbol to DCOY Reflecting Focus on Next-Generation Peptide Conjugate Therapeutics | SLRX Stock News

Salarius Pharmaceuticals(SLRX.US)